Xlife Sciences AGXSWX:XLS -11.06%50 Days Payable is 1,175.08 as of Dec. 2025, which is 172% above its 10-year median of 431.26. GuruFocus rates XSWX:XLS with a GF Score™ of 50/100 and a GF Value™ of CHF7.30 (Significantly Overvalued). The stock has 13 warning signs investors should review. Among 708 Biotechnology companies, Xlife Sciences AG ranks better than 86.44% on this metric.
The historical rank and industry rank for Xlife Sciences AG's Days Payable or its related term are showing as below:
XSWX:XLS'
s Days Payable Range Over the Past 10 Years
Min: 217.83 Med: 431.26 Max: 1279.42
Current: 1046.52
During the past 8 years, Xlife Sciences AG's highest Days Payable was 1279.42. The lowest was 217.83. And the median was 431.26.
XSWX:XLS's Days Payable is ranked better than 86.44% of 708
companies
in the Biotechnology industry
Industry Median: 113.56
vs XSWX:XLS: 1046.52
Xlife Sciences AG's Days Payable
increased
from Dec. 2024 (1,134.19) to Dec. 2025 (1,175.08).
It may suggest that Xlife Sciences AGdelayed paying its suppliers.
Xlife Sciences AG Days Payable Related Terms
Xlife Sciences AG Days Payable Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:XLS vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Xlife Sciences AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Days Payable distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Xlife Sciences AG's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (XSWX:XLS) has a Days Payable of 1,175.08 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Xlife Sciences AG and its competitors. This is 172% above median its historical median of 431.26. Over the past decade, Xlife Sciences AG's Days Payable has ranged from 217.83 to 1,279.42. According to the industry distribution chart, Xlife Sciences AG ranks #96 out of 708 companies in the Biotechnology industry, placing it in the top 13.6%.
Is Xlife Sciences AG's Days Payable too high?
Xlife Sciences AG's current Days Payable of 1,175.08 is 172% above median its 10-year median of 431.26. Over the past 10 years, this metric has ranged from a low of 217.83 to a high of 1,279.42. The Biotechnology industry median Days Payable is 113.56. Xlife Sciences AG's value of 1,175.08 is 934.8% above this industry median. Based on the distribution chart, Xlife Sciences AG ranks #96 out of 708 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #96 out of 708 companies for Days Payable. This places Xlife Sciences AG in the top 14% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. Xlife Sciences AG's value of 1,175.08 is 934.8% above this benchmark. Historically, Xlife Sciences AG's own Days Payable has ranged from 217.83 to 1,279.42 over the past decade. While the company's 10-year median is 431.26 vs. the industry median of 113.56, Xlife Sciences AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xlife Sciences AG's current Days Payable of 1,175.08 is 934.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Xlife Sciences AG and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current Days Payable is 1,175.08, which is 172% above median its own 10-year median of 431.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.30, compared to a current price of CHF20.90 — trading 186.3% above its estimated fair value. The current Days Payable is 1,175.08, which is 172% above median its 10-year median of 431.26 and 934.8% above the Biotechnology industry median of 113.56. Xlife Sciences AG's overall GF Score™ is 50/100 with 13 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Days Payable is 1,175.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF20.90 is trading 186.3% above its estimated GF Value™ of CHF7.30.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Days Payable: 1,175.08 (172% above median its 10-year median of 431.26)
GF Value™: CHF7.30 vs. price of CHF20.90 (186.3% above fair value)
Industry Position: 934.8% above the Biotechnology median (#96 of 708)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
50GF Score
Get the complete analysis for XSWX:XLS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
